Co-Diagnostics, Inc. Common Stock
Here’s whether Co-Diagnostics, Inc. Common Stock (CODX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: above the 50-day MA (medium-term momentum positive); 3-month momentum positive (+117.2%). Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-3.47% over 10 days); RSI 79 — overbought, elevated pullback risk; weak 1-year return of -29.8%; rising volume on a downtrend (distribution, 2.85x avg). Currently 89.1% off its 52-week high. Score: -3/7.
CODX is trading below its 200-day MA ($6.62) — a key warning sign the longer-term trend is under pressure. With an RSI of 78.9, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -29.8% compares to +27.9% for SPY (trailed the market by 57.6%). The current 89.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.